Loading clinical trials...
Loading clinical trials...
A Phase 1, Dose-escalation Study of MEDI-551, a Humanized Monoclonal Antibody Directed Against CD19, in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies
The primary objective of this study is to evaluate the safety and tolerability of MEDI-551 in Japanese patients with relapsed or refractory advanced B-cell malignancies.
Age
20 - 130 years
Sex
ALL
Healthy Volunteers
No
Research Site
Fukuoka, Japan
Research Site
Isehara-shi, Japan
Research Site
Nagoya, Japan
Start Date
May 25, 2011
Primary Completion Date
September 15, 2015
Completion Date
September 15, 2015
Last Updated
June 12, 2017
32
ACTUAL participants
MEDI-551
DRUG
Lead Sponsor
AstraZeneca
Collaborators
NCT05873205
NCT07148180
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions